Lindsay C. Strowd, MD

Review the PDF of the fact sheet on medications for advanced melanoma with board-relevant material. This fact sheet provides a list of the current US Food and Drug Administration approved medications for treatment of metastatic melanoma, and describes their mechanism of action and any related cutaneous side effects.

After, test your knowledge by answering the 5 practice questions.

Practice Questions

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

3. What medication can be administered as a subcutaneous injection?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

5. Which of the following medications is an IL-2 cytokine?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

The answers appear on the next page.

 

Practice Question Answers

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

3. What medication can be administered as a subcutaneous injection?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

5. Which of the following medications is an IL-2 cytokine?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

Review the PDF of the fact sheet on medications for advanced melanoma with board-relevant material. This fact sheet provides a list of the current US Food and Drug Administration approved medications for treatment of metastatic melanoma, and describes their mechanism of action and any related cutaneous side effects.

After, test your knowledge by answering the 5 practice questions.

Practice Questions

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

3. What medication can be administered as a subcutaneous injection?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

5. Which of the following medications is an IL-2 cytokine?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

The answers appear on the next page.

 

Practice Question Answers

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

3. What medication can be administered as a subcutaneous injection?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

5. Which of the following medications is an IL-2 cytokine?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

Review the PDF of the fact sheet on medications for advanced melanoma with board-relevant material. This fact sheet provides a list of the current US Food and Drug Administration approved medications for treatment of metastatic melanoma, and describes their mechanism of action and any related cutaneous side effects.

After, test your knowledge by answering the 5 practice questions.

Practice Questions

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

3. What medication can be administered as a subcutaneous injection?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

5. Which of the following medications is an IL-2 cytokine?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

The answers appear on the next page.

 

Practice Question Answers

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

3. What medication can be administered as a subcutaneous injection?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

5. Which of the following medications is an IL-2 cytokine?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib